Role of aspirin in primary prevention of cardiovascular disease

[1]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. , 2019, Circulation.

[2]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[3]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[4]  Deepak L. Bhatt,et al.  Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. , 2019, Gastroenterology.

[5]  A. Roddick,et al.  Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis , 2019, JAMA.

[6]  M. Mafham,et al.  Effects of aspirin for primary prevention in persons with diabetes mellitus: the ASCEND Study Collaborative Group , 2019, Journal of Vascular Surgery.

[7]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[8]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[9]  Suzanne G. Orchard,et al.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly , 2018, The New England journal of medicine.

[10]  C. Reid,et al.  Effect of Aspirin on All‐Cause Mortality in the Healthy Elderly , 2018, The New England journal of medicine.

[11]  C. Reid,et al.  Effect of Aspirin on Disability‐free Survival in the Healthy Elderly , 2018, The New England journal of medicine.

[12]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[13]  Jennifer S. Lin,et al.  Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[14]  M. Budoff,et al.  Coronary Calcium Score and Cardiovascular Risk. , 2018, Journal of the American College of Cardiology.

[15]  C. Patrono,et al.  The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting , 2018, Blood Cancer Journal.

[16]  C. Patrono,et al.  The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting , 2018, Blood Cancer Journal.

[17]  E. Grove,et al.  Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. , 2018, European heart journal.

[18]  R. Hunt,et al.  Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials , 2018, The lancet. Gastroenterology & hepatology.

[19]  T. Barbui,et al.  Essential thrombocythemia treatment algorithm 2018 , 2018, Blood Cancer Journal.

[20]  B. Di Camillo,et al.  In Silico Modeling of the Antiplatelet Pharmacodynamics of Low‐dose Aspirin in Health and Disease , 2017, Clinical pharmacology and therapeutics.

[21]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[22]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[23]  C. Patrono,et al.  Aspirin and Cancer. , 2016, Journal of the American College of Cardiology.

[24]  E. Whitlock,et al.  Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[25]  Evelyn Whitlock,et al.  Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[26]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[27]  C. Baigent.  Aspirin for Disease Prevention: Public Policy or Personal Choice? , 2016, Annals of Internal Medicine.

[28]  E. Whitlock,et al.  Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[29]  C. Patrono.  The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. , 2015, Journal of the American College of Cardiology.

[30]  C. Gachet.  Antiplatelet drugs: which targets for which treatments? , 2015, Journal of thrombosis and haemostasis : JTH.

[31]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[32]  K. Shimada,et al.  Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. , 2014, JAMA.

[33]  N. Cook,et al.  Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women , 2014, Heart.

[34]  Á. Lanas,et al.  Reappraisal of the clinical pharmacology of low‐dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action , 2014, Journal of thrombosis and haemostasis : JTH.

[35]  X. Y. Zhang,et al.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials , 2013, BDJ.

[36]  C. Tiemann,et al.  RGS5 is decreased in unstable human carotid plaque, and plays a role in the vascular smooth muscle cell/endothelial cell recruitment in vitro , 2013 .

[37]  Deepak L. Bhatt,et al.  Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review , 2012, Heart.

[38]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[39]  A. Hoes,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[40]  D. Adler,et al.  Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.

[41]  F. Santilli,et al.  The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes , 2012, Journal of thrombosis and haemostasis : JTH.

[42]  C. Patrono,et al.  Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. , 2012, Blood.

[43]  Jason C. Fish,et al.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[44]  N. Paynter,et al.  Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. , 2011, European heart journal.

[45]  D. Bauer,et al.  Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. , 2011, The American journal of medicine.

[46]  P. Sandercock,et al.  Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.

[47]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[48]  T. Morimoto,et al.  Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. , 2008, JAMA.

[49]  P. Macfarlane,et al.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.

[50]  J. Hirsh,et al.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[51]  G. Guyatt,et al.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[52]  F. Schmidt.  Meta-Analysis , 2008 .

[53]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[54]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[55]  C. Patrono,et al.  Determinants of the interindividual variability in response to antiplatelet drugs , 2005, Journal of thrombosis and haemostasis : JTH.

[56]  L. Melvin,et al.  Effects of estrogen with and without progestin on urinary incontinence , 2005, Journal of Family Planning and Reproductive Health Care.

[57]  T. Wilt,et al.  A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice? , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[58]  P. Malfertheiner,et al.  Peptic ulcer disease , 2002, The Lancet.

[59]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[60]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[61]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.

[62]  G. Gaetano,et al.  Drink in moderation, says consensus panel , 2001, The Lancet.

[63]  M. Roncaglioni.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.

[64]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[65]  T. Meade,et al.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.

[66]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[67]  Daniel Picot,et al.  The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.

[68]  F. Ferris.  Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.

[69]  G. Davı̀,et al.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.

[70]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[71]  G. Watkinson,et al.  Peptic ulcer disease , 1985, Digestive Diseases and Sciences.

[72]  G. FitzGerald,et al.  Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. , 1984, The New England journal of medicine.

[73]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[74]  F. Chan,et al.  Peptic ulcer disease , 1978, The Lancet.

[75]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[76]  Elizabeth M Webber,et al.  Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2016 .

[77]  C. Lindsell,et al.  randomized controlled trial. , 2014 .

[78]  H. J. Morris.  Standards of Medical Care in Diabetes , 2014 .

[79]  J. Cleland,et al.  Controversies in cardiovascular medicine Is aspirin useful in primary prevention ? , 2013 .

[80]  C. Patrono.  Controversies in cardiovascular medicine Low-dose aspirin in primary prevention : cardioprotection , chemoprevention , both , or neither ? , 2013 .

[81]  E. Akl,et al.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[82]  B. Gersh.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2010 .

[83]  J. Zalewska.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2009 .

[84]  R. Cífková,et al.  EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE , 2005 .

[85]  R. Cote,et al.  Detection of occult metastases , 1995 .

[86]  Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.

[87]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[88]  G. A. Moore,et al.  Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. , 1994, British heart journal.